MDV3100 in New Phase II Study (AZN) (MDVN) (PFE) (SNY)

Medivation, Inc. (MDVN) and Astellas Pharma, Inc. recently announced the initiation of a phase II study with their prostate cancer candidate, MDV3100. The study will evaluate MDV3100 as a monotherapy in hormone-na